Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6685587 | 1.00 | FDPS (0.41) | FDPSLMNADNM1TSHRTHRB | |
| SCHEMBL14238528 | 1.00 | FDPS (0.41) | FDPSLMNADNM1TSHRTHRB | |
| SCHEMBL24599674 | 1.00 | FDPS (0.41) | FDPSLMNADNM1TSHRTHRB | |
| SCHEMBL29342137 | 0.91 | OPRM1 (0.38) | FDPSLMNADNM1TSHRTHRB | |
| SCHEMBL21498956 | 0.91 | MC4R (0.41) | FDPSLMNADNM1OPRM1 | |
| SCHEMBL20462626 | 0.91 | MC4R (0.41) | FDPSLMNADNM1OPRM1 | |
| SCHEMBL19441073 | 0.91 | MC4R (0.41) | FDPSLMNADNM1OPRM1 | |
| SCHEMBL24040161 | 0.91 | OPRM1 (0.38) | FDPSLMNADNM1TSHRTHRB | |
| SCHEMBL19286074 | 0.91 | MC4R (0.41) | FDPSLMNADNM1OPRM1 | |
| SCHEMBL24486038 | 0.91 | FDPS (0.39) | FDPSLMNADNM1TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20220213109-A1 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2022-07-07 | — | — | US | disclosed |
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11161847-B2 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | TYMS, TYMP, DHFR | FDPS 160/4885LMNA 3865/4885DNM1 2353/4885 |
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | DHFR, TYMS, TYMP | FDPS 139/4885LMNA 3922/4885DNM1 3110/4885 |
| US-11161847-B2 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | FDPS 1269/4885LMNA 3909/4885DNM1 653/4885 |
| US-20220213109-A1 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | FDPS 1533/4885LMNA 3922/4885DNM1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.